Advanced search
Publication Cover
Journal of Immunotoxicology Volume 21, 2024 - Issue sup1
Submit an article Journal homepage
976
Views
0
CrossRef citations to date
0
Altmetric
Research Article

IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept

Luise A. Rosera Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Frankfurt am Main, GermanyCorrespondence[email protected]
View further author information
,
Christina Sakellarioub Department of Immunotechnology, Lund University, Lund, SwedenView further author information
,
Malin Lindstedtb Department of Immunotechnology, Lund University, Lund, SwedenORCID Iconhttps://orcid.org/0000-0001-9136-1087View further author information
ORCID Icon,
Vanessa Neuhausc Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Preclinical Pharmacology and In-Vitro Toxicology, Hannover, Germany;d Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Hannover, GermanyView further author information
,
Susann Dehmelc Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Preclinical Pharmacology and In-Vitro Toxicology, Hannover, Germany;d Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Hannover, GermanyView further author information
,
Charline Sommerc Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Preclinical Pharmacology and In-Vitro Toxicology, Hannover, Germany;d Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Hannover, GermanyView further author information
,
Martin Raasche Dynamic42 GmbH, Jena, GermanyView further author information
,
Thierry Flandref Translational Medicine, Novartis Institutes of Biomedical Research, Basel, SwitzerlandView further author information
,
Sigrid Roesenerg Chemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Philip Hewittg Chemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Michael J. Parnhama Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Frankfurt am Main, Germany;h EpiEndo Pharmaceuticals ehf, Reykjavík, IcelandView further author information
,
Katherina Sewaldc Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Preclinical Pharmacology and In-Vitro Toxicology, Hannover, Germany;d Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Hannover, GermanyView further author information
&
Susanne Schiffmannh EpiEndo Pharmaceuticals ehf, Reykjavík, IcelandORCID Iconhttps://orcid.org/0000-0001-5035-2504View further author information
ORCID Icon show all
Article: 2332177 | Received 10 Jul 2023, Accepted 13 Mar 2024, Published online: 05 Apr 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.